CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
1 research outputs found
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Author
Altekruse
Amy O'Sullivan
+37Â more
Blade
Brenner
Daniel Normolle
Dimopoulos
Dimopoulos
Dispenzieri
Durie
Fayers
Fenk
G. David Roodman
Gaul
Jeffrey A. Zonder
John Waas
Kapoor
Knop
Kumar
Kyle
Li
Lijun Dai
Lopez-Girona
Markus Y. Mapara
Michael Boyiadzis
Mohammad Abbas
Mounzer Agha
Palumbo
Ponisch
Ponisch
Rajkumar
Ramasamy
Ryan C. Kennedy
Silvana Lalo Pregja
Steve Burt
Suzanne Lentzsch
Weber
Weide
Yongli Shuai
Zhu
Publication venue
'American Society of Hematology'
Publication date
Field of study
No full text
Crossref